ESPE Abstracts (2015) 84 P-3-1026

Fasting and Post-Meal Levels of Appetite Regulating Hormones, before and Following GH Treatment, in Children with Idiopathic Short Stature

Michal Yackobovitch-Gavana,b, Galia Gat-Yablonskia,b, Biana Shtaifb,c, Moshe Phillipa,b & Liora Lazara,b


aThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel; bSackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel; cFelsenstein Medical Research Center, Petah Tikva, Israel


Background: Poor appetite is common in children with idiopathic short stature (ISS), and is usually improved with GH therapy.

Objective and hypotheses: To investigate the effect of GH therapy on appetite regulating hormones following a standard meal test (SMT) and to examine the association between these changes and growth response, body composition and resting energy expenditure (REE).

Method: Nine ISS pre-pubertal children underwent a SMT before and 4 months following initiation of GH. Leptin, ghrelin, GLP1 and insulin levels were measured; area under the curve (AUC) was calculated. Height, weight, body composition and REE were recorded at baseline and after 4 and 12 months.

Results: Following 4 months of GH therapy, an improvement in appetite was reported and a significant increase in height-SDS (P=0.011), weight-S.D.s (P=0.021) and REE (P=0.025) were observed. At 4 months, an increase in fasting insulin levels (P=0.043), a decrease in fasting GLP1 levels (P=0.038) and a decrease in fasting and meal’s AUC ghrelin levels (P=0.051) were observed, while leptin levels remained unchanged. The incremental response of ghrelin and GLP1 to SMT (ghrelin-continuous decrease, GLP-1 – initial rise and subsequent fall), were similar before and during GH treatment. Ghrelin levels before GH treatment were positively correlated with the changes in weight-S.D.s and REE (fasting: r=0.667, P=0.05 and r=0.866, P=0.005 respectively; AUC: r=0.788, P=0.012, r=0.847, P=0.008 respectively). Ghrelin AUC levels at 4 months, were positively correlated with the changes in Ht-S.D.s (r=0.741, P=0.022) and free-fat-mass (r=0.890, P=0.001) at 12 months of GH treatment.

Conclusion: The significant reduction in ghrelin and GLP1 following GH treatment suggests a possible role for GH in appetite regulation. Fasting and meal-AUC levels of ghrelin may serve as biomarkers for predicting growth response to GH treatment. The mechanism linking GH with changes in appetite regulating hormones remain to be elucidated.

Article tools

My recent searches

No recent searches.